Source comparison
Summary: TB-500 versus Follistatin for muscle research
TB-500 and Follistatin are mechanistically non-redundant in muscle biology. TB-500 enhances the upstream cytoskeletal and migratory phases of satellite cell response — G-actin sequestration, ILK-Wnt activation, and directional migration — ensuring that an adeq
This comparison does not assign a generated winner or score.
- TB-500 and Follistatin are mechanistically non-redundant in muscle biology. TB-500 enhances the upstream cytoskeletal and migratory phases of satellite cell response — G-actin sequestration, ILK-Wnt activation, and directional migration — ensuring that an adequate progenitor pool assembles at the injury nidus. Follistatin removes the downstream transcriptional brake on myoblast differentiation — SMAD2/3-mediated repression of myogenin and MHC expression — allowing the assembled progenitor pool to commit to terminal differentiation and form functional myotubes efficiently.
- Research designs that aim to characterise these mechanisms independently require staged endpoint sampling, isoform-specific Follistatin selection (FST-315 for muscle-only biology), appropriate pathway-specific inhibitor controls (cytochalasin D for TB-500; MSTN−/−, SB431542, or ActRIIB-Fc for Follistatin), and recognition that TB-500 effects are temporally maximal during the first week post-injury while Follistatin effects on terminal differentiation are maximal during the second and third weeks.
- Simultaneous or sequential administration of both compounds in properly controlled experiments offers a uniquely informative approach to dissecting the sequential biology of muscle regeneration at two distinct regulatory levels — cytoskeletal dynamics and TGF-β superfamily transcriptional control — within a single model system.
- William is a research analyst at Peptides Lab UK, specialising in research peptides, laboratory compounds, and sourcing standards for high-purity peptide products.